EASTONBIOPHARMACEUTICALS(SH:688513) Xin Lang Cai Jing·2025-07-24 09:17Core Viewpoint - Yuan Dong Bio is accelerating its transformation from generic to innovative drugs, with a strong commitment to innovation as the core driver of high-quality development [2][4]. Company Overview - Chengdu Yuan Dong Bio-Pharmaceutical Co., Ltd. was established in 2009 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 2, 2020, with stock code 688513 [4]. - The company focuses on research and development driven by innovation, integrating the entire industry chain of chemical raw materials, high-end chemical drugs, and biological drugs [4]. - Yuan Dong Bio aims to become a leading enterprise in the global anesthesia and analgesia field, with a mission centered on patient care and human health [4]. New Quality Productivity - The core of "new quality productivity" in the biopharmaceutical industry lies in technological innovation and the transformation of results [5]. - A multi-dimensional collaborative breakthrough is essential for cultivating new quality productivity, requiring technological innovation, policy support, and a complete industrial development ecosystem [5]. Business Strategy - The company’s development strategy is based on high-end generic drugs, internationalization for growth, and innovation for the future [6]. - High-end generic drugs currently serve as the main source of revenue and profit, with a steady increase in the number of approvals over the past three years [6]. - As of the end of 2024, the company has successfully industrialized 60 high-end chemical drugs, including several first generics and special narcotic drugs [6]. International Expansion - Yuan Dong Bio is actively developing international markets while deepening its domestic market presence [6]. - By the end of 2024, the company has exported 12 raw materials to major international markets and received FDA approval for 2 high-end formulation products [6]. Innovation and R&D - The company maintains a high level of R&D investment, with over 20% of revenue allocated to R&D in recent years, exceeding the industry average [8]. - There are currently over 10 first-class new drugs in the R&D pipeline, ensuring a structured layout for industrial upgrades [7][8]. - The efficiency of R&D results transformation is continuously improving, with an increasing number of product approvals in high-end generics and several new drug pipelines at different stages of development [8]. Future Outlook - Yuan Dong Bio is committed to developing differentiated clinical advantages in innovative products and high-end formulations to enhance market competitiveness [9].